# UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

#### SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934  (AMENDMENT NO) *
Enzon Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
293904-10-8
(CUSIP Number)
May 20, 2003
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
/ / Rule 13d-1(b) /x/ Rule 13d-1(c) / / Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Page 1 of 7 Pages
SCHEDULE 13G
CUSIP NO. 293904-10-8 Page 2 of 7 Pages
(1) NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Citigroup Global Markets Holdings Inc. f/k/a "Salomon Smith Barney Holdings Inc."
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a) / / (b) / /
(3) SEC USE ONLY

(4)	CITIZENSHIP OR PLACE	OF ORGANIZATION	New York
	NUMBER OF	(5) SOLE VOTING POWER	0
	SHARES		
	BENEFICIALLY	(6) SHARED VOTING POWER	2,290,751*
	OWNED BY		
	EACH	(7) SOLE DISPOSITIVE POWER	0
	REPORTING		
	PERSON	(8) SHARED DISPOSITIVE POWER	2,290,751*
	WITH:		
(9)		FICIALLY OWNED BY EACH REPORTING PERSON	
(10)		TE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHA	
(11)		RESENTED BY AMOUNT IN ROW (9)	5.3%*
(12)	TYPE OF REPORTING PE	RSON (SEE INSTRUCTIONS)	НС
 * As:		cise of certain securities held.	
		SCHEDULE 13G	
CUSI	P NO. 293904-10-8	Pag	e 3 of 7 Pages
(1)	NAMES OF REPORTING P	ERSONS N NOS. OF ABOVE PERSONS (ENTITIES ONLY)	
	Citigroup Inc.		
(2)	CHECK THE APPROPRIAT	E BOX IF A MEMBER OF A GROUP (SEE INSTRUC	TIONS)
			(a) / / (b) / /
(3)	SEC USE ONLY		
(4)	CITIZENSHIP OR PLACE	OF ORGANIZATION	Delaware
	NUMBER OF	(5) SOLE VOTING POWER	0

BENEFICIA		
	ALLY (6) SHARED VOTING POWER	2,294,255*
OWNED E	BY	^^
EACH	(7) SOLE DISPOSITIVE POWER	0
REPORTIN		
PERSON	(8) SHARED DISPOSITIVE POWER	2,294,255* **
WITH:		
(9) AGGREGATE	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
(10) CHECK IF	THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHAF	
	DF CLASS REPRESENTED BY AMOUNT IN ROW (9)	5.3%* **
(12) TYPE OF F	REPORTING PERSON (SEE INSTRUCTIONS)	НС
l- 3	nversion/exercise of certain securities held.	
	hares held by the other reporting person.	
** Includes sh		
** Includes sh	hares held by the other reporting person.	
** Includes sh	hares held by the other reporting person.  Name of Issuer:	
** Includes sh	Name of Issuer:  Enzon Pharmaceuticals, Inc.	
** Includes sh	Name of Issuer:  Enzon Pharmaceuticals, Inc.  Address of Issuer's Principal Executive Offices:  685 Route 202/206  Bridgewater, New Jersey 08807	
** Includes should the should be sho	Name of Issuer:  Enzon Pharmaceuticals, Inc.  Address of Issuer's Principal Executive Offices:  685 Route 202/206  Bridgewater, New Jersey 08807	gs")
<pre>s* Includes sh Item 1(a). Item 1(b).</pre>	Name of Issuer:  Enzon Pharmaceuticals, Inc.  Address of Issuer's Principal Executive Offices:  685 Route 202/206 Bridgewater, New Jersey 08807  Name of Person Filing:  Citigroup Global Markets Holdings Inc. ("CGM Holding	gs")
<pre>s* Includes sh Item 1(a). Item 1(b).</pre>	Name of Issuer:  Enzon Pharmaceuticals, Inc.  Address of Issuer's Principal Executive Offices: 685 Route 202/206 Bridgewater, New Jersey 08807  Name of Person Filing: Citigroup Global Markets Holdings Inc. ("CGM Holding Citigroup Inc. ("Citigroup")	
<pre>s* Includes sh Item 1(a). Item 1(b).</pre>	Name of Issuer:  Enzon Pharmaceuticals, Inc.  Address of Issuer's Principal Executive Offices:  685 Route 202/206 Bridgewater, New Jersey 08807  Name of Person Filing:  Citigroup Global Markets Holdings Inc. ("CGM Holding Citigroup Inc. ("Citigroup")  Address or Principal Office or, if none, Residence:	
<pre>s* Includes sh Item 1(a). Item 1(b).</pre>	Name of Issuer:  Enzon Pharmaceuticals, Inc.  Address of Issuer's Principal Executive Offices:  685 Route 202/206 Bridgewater, New Jersey 08807  Name of Person Filing:  Citigroup Global Markets Holdings Inc. ("CGM Holding Citigroup Inc. ("Citigroup")  Address or Principal Office or, if none, Residence:  The address of the principal office of CGM Holdings 388 Greenwich Street	is:
** Includes should the should be sho	Name of Issuer:  Enzon Pharmaceuticals, Inc.  Address of Issuer's Principal Executive Offices:  685 Route 202/206 Bridgewater, New Jersey 08807  Name of Person Filing:  Citigroup Global Markets Holdings Inc. ("CGM Holding Citigroup Inc. ("Citigroup")  Address or Principal Office or, if none, Residence: The address of the principal office of CGM Holdings 388 Greenwich Street New York, NY 10013	is:
<pre>item 1(a). Item 1(b). Item 2(a).</pre>	Name of Issuer:  Enzon Pharmaceuticals, Inc.  Address of Issuer's Principal Executive Offices:  685 Route 202/206 Bridgewater, New Jersey 08807  Name of Person Filing:  Citigroup Global Markets Holdings Inc. ("CGM Holding Citigroup Inc. ("Citigroup")  Address or Principal Office or, if none, Residence:  The address of the principal office of CGM Holdings  388 Greenwich Street New York, NY 10013  The address of the principal office of Citigroup is:  399 Park Avenue	is:
<pre>item 1(a). Item 1(b). Item 2(a).</pre>	Name of Issuer:  Enzon Pharmaceuticals, Inc.  Address of Issuer's Principal Executive Offices: 685 Route 202/206 Bridgewater, New Jersey 08807  Name of Person Filing:  Citigroup Global Markets Holdings Inc. ("CGM Holding Citigroup Inc. ("Citigroup")  Address or Principal Office or, if none, Residence: The address of the principal office of CGM Holdings 388 Greenwich Street New York, NY 10013  The address of the principal office of Citigroup is: 399 Park Avenue New York, NY 10043	is:
<pre>f** Includes sh Item 1(a). Item 1(b). Item 2(a).</pre>	Name of Issuer:  Enzon Pharmaceuticals, Inc.  Address of Issuer's Principal Executive Offices: 685 Route 202/206 Bridgewater, New Jersey 08807  Name of Person Filing: Citigroup Global Markets Holdings Inc. ("CGM Holding Citigroup Inc. ("Citigroup")  Address or Principal Office or, if none, Residence: The address of the principal office of CGM Holdings 388 Greenwich Street New York, NY 10013  The address of the principal office of Citigroup is: 399 Park Avenue New York, NY 10043  Citizenship or Place of Organization:	is:

Common Stock

293904-10-5

# Page 4 of 7 Pages

- Item 3. If this Statement is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing is a(n):
  - (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 780);
  - (b) [] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
  - (c) [] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
  - (d) [ ] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
  - (e) [ ] Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);
  - (f) [] Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);
  - (g) [ ] Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);
  - (h) [ ] Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
  - (i) [ ] Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3)
  - (j) [ ] Group, in accordance with Section 240.13d-1 (b) (1) (ii) (J).
- Item 4. Ownership. (as of May 20, 2003)
  - (a) Amount beneficially owned: See item 9 of cover pages
  - (b) Percent of Class: See item 11 of cover pages
  - (c) Number of shares as to which the person has:
    - (i) sole power to vote or to direct the vote:
    - (ii) shared power to vote or to direct the vote:
    - (iii) sole power to dispose or to direct the disposition of:
    - (iv) shared power to dispose or to direct the disposition of:

See Items 5-8 of cover pages

Page 5 of 7 Pages

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

Not Applicable.

Item 7. Identification and Classification of the Subsidiary which Acquired the Security being Reported on by the Parent Holding Company.

See Exhibit 2 for the identity of the subsidiaries which directly beneficially own the securities reported herein.

Item 8. Identification and Classification of Members of the Group.

Not Applicable.

Item 9. Notice of Dissolution of Group.

Not Applicable.

Page 6 of 7 Pages

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: May 29, 2003

CITIGROUP GLOBAL MARKETS HOLDINGS INC.

By: /s/ Joseph B. Wollard

Name: Joseph B. Wollard Title: Assistant Secretary

CITIGROUP INC.

By: /s/ Serena D. Moe

Name: Serena D Moe

Name: Serena D. Moe Title: Assistant Secretary

Page 7 of 7 Pages

EXHIBIT INDEX TO SCHEDULE 13G

-----

Agreement between CGM Holdings and Citigroup as to joint filing of Schedule 13G

EXHIBIT 2

-----

Identification of the Subsidiaries which acquired the securities being reported by the Parent Holding Company(s).

### EXHIBIT 1

### AGREEMENT AS TO JOINT FILING OF SCHEDULE 13G

Each of the undersigned hereby affirms that it is individually eligible to use Schedule 13G, and agrees that this Schedule 13G is filed on its behalf.

Date: May 29, 2003

CITIGROUP GLOBAL MARKETS HOLDINGS INC.

By: /s/ Joseph B. Wollard

-----

Name: Joseph B. Wollard Title: Assistant Secretary

CITIGROUP INC.

By: /s/ Serena D. Moe

-----

Name: Serena D. Moe

Title: Assistant Secretary

## EXHIBIT 2

#### IDENTIFICATION OF SUBSIDIARY(S) WHICH ACQUIRED SECURITIES

Smith Barney Fund Management LLC and Citigroup Global Markets Limited

Each of the undersigned hereby affirms the identification of the subsidiary(s) which acquired the securities filed for in this Schedule 13G.

Date: May 29, 2003

CITIGROUP GLOBAL MARKETS HOLDINGS INC.

By: /s/ Joseph B. Wollard

Name: Joseph B. Wollard Title: Assistant Secretary

CITIGROUP INC.

By: /s/ Serena D. Moe

-----

Name: Serena D. Moe Title: Assistant Secretary